218 related articles for article (PubMed ID: 16951768)
1. Does thymidine phosphorylase correlate with angiogenesis in intraductal carcinoma of the breast?
Erkus M; Meteoglu I; Culhaci N; Meydan N; Erdogdu I
Saudi Med J; 2006 Sep; 27(9):1329-33. PubMed ID: 16951768
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of thymidine phosphorylase expression is associated with a discrete pattern of angiogenesis in ductal carcinomas in situ of the breast.
Engels K; Fox SB; Whitehouse RM; Gatter KC; Harris AL
J Pathol; 1997 Aug; 182(4):414-20. PubMed ID: 9306962
[TBL] [Abstract][Full Text] [Related]
3. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast.
Lee AH; Dublin EA; Bobrow LG
J Pathol; 1999 Feb; 187(3):285-90. PubMed ID: 10398080
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
Vogl G; Dietze O; Hauser-Kronberger C
Histopathology; 2005 Dec; 47(6):617-24. PubMed ID: 16324200
[TBL] [Abstract][Full Text] [Related]
5. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
6. Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast.
Teo NB; Shoker BS; Jarvis C; Sloane JP; Holcombe C
J Clin Pathol; 2003 Dec; 56(12):919-23. PubMed ID: 14645350
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ELISA level and immunohistochemical status for thymidine phosphorylase (TP) in invasive breast carcinoma.
Kurosumi M; Sugamata N; Tabei T; Inoue K; Matsumoto H; Suemasu K; Higashi Y
Anticancer Res; 2002; 22(1A):331-8. PubMed ID: 12017313
[TBL] [Abstract][Full Text] [Related]
8. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
11. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
12. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
[TBL] [Abstract][Full Text] [Related]
13. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
14. Breast carcinogenesis. Transition from hyperplasia to invasive lesions.
Meteoglu I; Dikicioglu E; Erkus M; Culhaci N; Kacar F; Ozkara E; Uyar M
Saudi Med J; 2005 Dec; 26(12):1889-96. PubMed ID: 16380768
[TBL] [Abstract][Full Text] [Related]
15. Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast.
Zolota V; Gerokosta A; Melachrinou M; Kominea A; Aletra C; Scopa CD
Anticancer Res; 1999; 19(4B):3269-74. PubMed ID: 10652623
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemical tumor markers in infiltrating ductal breast carcinoma].
Gallegos M; González S; León A; Claure R; Goñi I; Andrade L; Duarte I
Rev Med Chil; 1998 Oct; 126(10):1216-23. PubMed ID: 10030093
[TBL] [Abstract][Full Text] [Related]
17. Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast.
Sapino A; Bongiovanni M; Cassoni P; Righi L; Arisio R; Deaglio S; Malavasi F
J Pathol; 2001 Jun; 194(2):254-61. PubMed ID: 11400156
[TBL] [Abstract][Full Text] [Related]
18. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
19. Predictors of disease progression in ductal carcinoma in situ of the breast and vascular patterns.
Adler EH; Sunkara JL; Patchefsky AS; Koss LG; Oktay MH
Hum Pathol; 2012 Apr; 43(4):550-6. PubMed ID: 21925705
[TBL] [Abstract][Full Text] [Related]
20. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast.
Tan PH; Chuah KL; Chiang G; Wong CY; Dong F; Bay BH
Oncol Rep; 2002; 9(5):1081-6. PubMed ID: 12168077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
